GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Price-to-Owner-Earnings

Peptron (XKRX:087010) Price-to-Owner-Earnings : (As of Sep. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Peptron Price-to-Owner-Earnings?

As of today (2024-09-23), Peptron's share price is ₩53200.00. Peptron does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Peptron's Price-to-Owner-Earnings or its related term are showing as below:


XKRX:087010's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.425
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-09-23), Peptron's share price is ₩53200.00. Peptron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-954.00. Therefore, Peptron's PE Ratio for today is At Loss.

As of today (2024-09-23), Peptron's share price is ₩53200.00. Peptron's EPS without NRI for the trailing twelve months (TTM) ended in was ₩-823.52. Therefore, Peptron's PE Ratio without NRI for today is At Loss.


Peptron Price-to-Owner-Earnings Historical Data

The historical data trend for Peptron's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Price-to-Owner-Earnings Chart

Peptron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Peptron Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Peptron's Price-to-Owner-Earnings

For the Biotechnology subindustry, Peptron's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peptron's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peptron's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Peptron's Price-to-Owner-Earnings falls into.



Peptron Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Peptron's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=53200.00/-840.86
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Peptron  (XKRX:087010) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Peptron Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Peptron's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Peptron Business Description

Traded in Other Exchanges
N/A
Address
37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron Headlines

No Headlines